Abbott CEO: ‘We’re right on time’ to the PFA party
As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors that the company is not just playing defense.
Medtronic, Boston Scientific and Johnson & Johnson have already debuted PFA systems in the U.S. However, Abbott is preparing to launch its own system next year.
“I don't think it's a question of Abbott being late,” Ford said on an earnings call. “We're right on time, and we're complete with the full portfolio.”
Cardiac ablation is used to treat heart rhythm disorders, and PFA is quickly becoming the preferred method, due to its potential for safer and faster procedures.
Author's summary: Abbott CEO says company is on track.
More News
- Etihad Airways Adds New 8-Hour Airbus A321LR Flights To Europe
- ‘Reviewing it’: Hegseth on releasing video of Caribbean strike; survivors died on alleged drug boat
- Kayla Harrison’s Shredded UFC 324 Faceoff Look Sends Fans Into A Frenzy
- 01 – Air Libre - Podcasts
- Etihad's fly-past marks F1 finale in Abu Dhabi
- Etihad’s A380 to Tokyo in Summer 2026
- Steve Cropper, Stax Records and Blues Brothers Guitarist, Dies at 84
- Etihad to welcome over 2 million December passengers as winter travel demand soars
- Paddy Pimblett's Bold Prediction For Justin Gaethje UFC Fight
- ‘My heart is broken’: Domestic worker mourns sister who died in Hong Kong fire